Incyte Corp. — Sponsor Intelligence | 61 EU Trials

Filter these 61 trials by condition, phase, country and more.

Open in Search →

61 Registered trials

19 Recruiting

37 Completed trials

21 Countries active

52 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I

Phase III: 29 Phase II/III: 1 Phase II: 16 Phase I/II: 4 Phase I: 7 Phase I (Other): 4

Oversight events:

4 temporary halts across 1 trial

View oversight register →

100%

37 of 37 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Chronic graft versus host disease 5 Vitiligo 5 Myelofibrosis 3 Non-small cell lung cancer 3 Malignant melanoma stage IV 3 Non-small cell lung cancer stage IV 3 Diffuse large B-cell lymphoma 3 Metastatic malignant melanoma 3 Non-small cell lung cancer metastatic 3 Hepatocellular carcinoma 2 Ovarian cancer 2 Myeloproliferative neoplasm 2

Top IMPs

RUXOLITINIB 12 4-[3-(CYANOMETHYL)-3-(3',5'-DIMETHYL-1H,1'H-[4,4'-BIPYRAZOL]-1-YL)AZETIDIN-1-YL]-2,5-DIFLUORO-N-[(2S)-1,1,1-TRIFLUOROPROPAN-2-YL]BENZAMIDE 7 TAFASITAMAB 7 POVORCITINIB 5 AXATILIMAB 4 INCB099280 4 RETIFANLIMAB 4 LENALIDOMIDE 3 PEMIGATINIB 3 8-ETHOXY-N-((3R,4S)-3-METHYL-1-(METHYLSULFONYL)PIPERIDIN-4-YL)-7-(1H-PYRAZOL-4-YL)-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-2-AMINE 2 CARBOPLATIN 2 CISPLATIN 2

All trials

61 total

IMPD-Q-only application Not authorised

2025-524730-26-00 Phase I (Other) 1 country
Phase 3 Study of INCB123667 Versus Investigator's Choice of Chemotherapy in Platinum Resistant Ovarian Cancer With Cyclin E1 Overexpression Pending

2025-522748-42-00 Phase III 8 countries 8-ETHOXY-N-((3R,4S)-3-METHYL-1-(METHYLSULFONYL)PIPERIDIN-4-YL)-7-(1H-PYRAZOL-4-Y…
A Phase 1, Open-Label, Multicenter Study of INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies Pending

2025-523130-11-00 Phase I 3 countries
A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treat… Pending

2025-523735-19-00 Phase III 10 countries INCA33890
A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic P… Pending

2025-525009-18-00 Phase III 11 countries INCB161734 HYDROCHLORIDE DIHYDRATE; PACLITAXEL ALBUMIN-BOUND
A Phase 1, Open-Label, Multicenter Study of INCB160058 in Participants With Myeloproliferative Neoplasms. Recruiting

2024-520353-21-00 Phase I (Other) 4 countries
Selective Treatment of Oral Povorcitinib Long-Term Rollover Study (STOP-LTR) Recruiting

2024-520107-12-00 Phase III 13 countries 4-[3-(CYANOMETHYL)-3-(3',5'-DIMETHYL-1H,1'H-[4,4'-BIPYRAZOL]-1-YL)AZETIDIN-1-YL]…
A Phase 3, Randomized, Open-Label Study of Axatilimab Versus Best Available Therapy in Participants With Chronic Graft-Versus-Host Disease A… Recruiting

2024-518973-32-00 Phase III 14 countries AXATILIMAB
Selective Treatment of Oral Povorcitinib in Prurigo Nodularis Study 1 (STOP-PN1) Recruiting

2024-511879-16-00 Phase III 7 countries 4-[3-(CYANOMETHYL)-3-(3',5'-DIMETHYL-1H,1'H-[4,4'-BIPYRAZOL]-1-YL)AZETIDIN-1-YL]…
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms Recruiting

2023-506145-38-00 Phase I (Other) 3 countries
A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Parsacl… Recruiting

2022-501687-18-00 Phase II 8 countries IBRUTINIB; PARSACLISIB HYDROCHLORIDE; RUXOLITINIB; TAFASITAMAB
Phase 2a Study of Tafasitamab in Adults With Primary Autoimmune Blood Cell Disorders Recruiting

2025-521286-27-00 Phase II/III 4 countries TAFASITAMAB
A Phase 2, Randomized, Open-Label Study Of Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft Versus Host… Recruiting

2025-521849-25-00 Phase II 4 countries AXATILIMAB
Phase 2 Study of INCB123667 in Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression Recruiting

2025-521513-14-00 Phase II 2 countries 8-ETHOXY-N-((3R,4S)-3-METHYL-1-(METHYLSULFONYL)PIPERIDIN-4-YL)-7-(1H-PYRAZOL-4-Y…
Study of Ruxolitinib Cream in Participants with Hidradenitis Suppurativa (TRuE-HS1) Recruiting

2024-517632-22-00 Phase III 6 countries RUXOLITINIB
A study to evaluate the efficacy and safety of ruxolitinib cream in children (6 to <12 years old) with non-segmental vitiligo Recruiting

2024-513171-41-00 Phase III 12 countries RUXOLITINIB
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Axatilimab (INCA034176) and Corticosteroids as Initial Treatment for Chroni… Recruiting

2023-510292-65-00 Phase III 8 countries AXATILIMAB
Ruxolitinib rollover study Recruiting

2023-507225-42-00 Phase II 1 country RUXOLITINIB
A study to evaluate the effects and safety of INCA033989 in participants with myelofibrosis or essential thrombocythemia Recruiting

2022-502514-86-00 Phase I 5 countries
A Phase 1, Open-Label, Multicenter Study of INCA033890 in Participants with Advanced or Metastatic Solid Tumors Recruiting

2022-502456-31-00 Phase I 4 countries
A continued study in patients with Hematologic Cancers previously treated with Tafasitamab. Recruiting

2022-500765-27-00 Phase III 3 countries TAFASITAMAB
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy and in Combination With Anticancer Therapies in Participants With Sele… Recruiting

2024-512822-28-00 Phase I 3 countries
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of INCB000928 in Participan… Recruiting

2023-504129-38-00 Phase II 6 countries INCB000928
A study evaluating the safety and efficacy of ponatinib for the treatment of recurrent or refractory leukemias or solid tumors in children Recruiting

2023-509699-41-00 Phase I/II 6 countries PONATINIB

Showing 1–24 of 61 trials

← All sponsors A–Z